Sign In

SpePharm Holding, B.V.

SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market. Particular therapeutic areas of interest are oncology and hematology, critical and supportive care, and endocrinology. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside Europe, seeking to maximize product and commercial opportunities in Europe.

• Show past press releases
• Edit this company

Elevator Pitch
SpePharm markets high medical value specialty medicines in Europe for the hospital market. The Company, founded in 2006 and located in Amsterdam and Paris, has two current products: Loramyc®, marketed in a joint venture with BioAlliance Pharma for oral candidiasis and MuGard™ licensed from Access Pharma in August 2007 and marketed for oral mucositis. SpePharm is the partner for choice for pan-European marketing of hospital medicines.

Contact Information
Kingsfordweg 151
Amsterdam 1043 GR
+31 (0)20 491 9602
+31 (0)20 491 9090
Jean-Francois Labbé
+33 (0)1 56 60 56 60

Company Facts
Founded:Sep 2006
Founders:Dr Jean-Francois Labbé, Dr Caroline Dumas, Dr Neil Brown
CEO:Dr Jean-Francois Labbé
CTO or technical lead:CMO: Dr Caroline Dumas
CFO or finance director:Kurt Schmidt
Head of Sales:CBO: Dr Neil Brown
Head of Marketing:

Category:Biotechnology & Healthcare
Sector:Other Biotechnology & Healthcare
Funding raised:Yes
Funding sought:
Seeking Partnerships:

Non-executive Board Members

  • Hubert Birner, Partner, TVM Capital
  • James C. Gale, Partner, Signet Healthcare Partners
  • Bernd Seibel, General Partner, CFO European Operations , TVM Capital

    Key Customers

    Key Business Partners

  • BioAlliance Pharma
  • Access Pharmaceuticals Inc

    Key Competitors

    Capital Raised
    To view this information you must be signed in and subscribed to the online dataservice, sign in here.

    To read more about the Online data service click here

    Public Offerings
    No public offerings

  • Data

    Tech investments
    From our Online Data Service
    VC-backed companies
    From our Radar

    Recent Deals

    Oct 19€3.0MInternet services
    Oct 19€6.0MBusiness applications
    Oct 18€11.0MConsumer electronics
    Oct 18€5.0MBusiness applications
    Oct 18€2.3MInternet services
    Oct 17€5.9MBiopharmaceuticals
    Oct 16€51.0MArtificial Intelligence

    For information on Europe's most extensive database on technology funding click here!


    Press Releases

    May 28
    identiq raises $5m seed, launches privacy-first identity validation...

    Apr 29
    nethone raised over $1 million from innovation nest

    Oct 1
    The Link App
    the link app launches version 2.0

    Mar 29
    Addex Therapeutics
    addex sucessfully raises chf40 million in capital increase

    Jan 2
    Urban Jungle
    urban jungle raises £1m in seed funding to build tech-enabled home ...

    About usContact usLegal Information
    Copyright © 1999-2019
    Emerging Technology Research Europe Inc. All rights reserved.